Acme United (ACU) Q2 2026 Earnings Beat Driven by MyMedic Acquisition and Margin Expansion

• Acme United (ACU) reported Q2 2026 EPS of $1.22, significantly beating the $0.81 consensus estimate, while revenue reached $62.7 million against $58.1 million expected.
• The revenue growth was primarily fueled by the acquisition of MyMedic, with organic growth standing at 8% year-over-year.
• Gross margins expanded to 42.6% from 41.0% in the prior year, driven by operational efficiencies and a strategic shift in inventory costs.
• Investors should monitor key risks including elevated SG&A expenses at 32% of sales and potential headwinds from tariffs and freight costs.

Acme United Corporation (ACU) delivered a robust performance for the second quarter of fiscal 2026, significantly surpassing analyst expectations across both top-line and bottom-line metrics. The company reported earnings per share (EPS) of $1.22, a substantial improvement over the consensus forecast of $0.81. Revenue climbed to $62.7 million, eclipsing the projected $58.1 million, marking a 16% year-over-year increase. This strong financial showing prompted an immediate market reaction, with shares surging approximately 12% to near a 52-week high of $51.88 following the earnings release .

The primary catalyst for this revenue growth was the acquisition of MyMedic, a strategic move that has allowed the company to expand its product portfolio and distribution channels. Excluding the contribution from MyMedic, Acme United demonstrated solid underlying business health with an organic growth rate of 8%. This dual driver of inorganic expansion and steady organic performance highlights the company's ability to leverage acquisitions for immediate top-line impact while maintaining a resilient core business. The integration of MyMedic remains a focal point for management, with plans to expand the brand's distribution beyond its current direct-to-consumer model into mass retail channels .

Profitability metrics also showed marked improvement, with gross margins expanding to 42.6% compared to 41.0% in the same period last year . CEO Johnsen attributed this margin expansion to operational efficiencies and a deliberate transition from higher-tariff inventory to lower-cost stock . Management expects this margin recovery trajectory to continue through the remainder of the fiscal year as the inventory transition is completed. This strategic shift is critical for maintaining profitability in an environment where input costs and tariffs have historically pressured margins.

How Does MyMedic Integration Impact Future Growth?

The integration of MyMedic is not merely a financial transaction but a strategic pivot aimed at diversifying revenue streams and expanding market reach. By moving into mass retail, Acme United aims to capitalize on broader consumer bases and reduce reliance on direct-to-consumer channels, which can be subject to higher customer acquisition costs. This expansion is expected to drive strong profitability in the fourth quarter, a period traditionally buoyed by seasonal demand . The company's ability to successfully integrate MyMedic while maintaining its core operational efficiency will be a key determinant of long-term growth.

However, the integration process also introduces complexities that investors must monitor. The company's selling, general, and administrative (SG&A) expenses remain elevated at 32% of sales, a figure that management acknowledges as a near-term headwind . While the acquisition drives revenue, the associated costs of integration and expanded operations can temporarily compress net margins. Investors should watch for signs of SG&A optimization as the company scales the MyMedic brand and achieves synergies from the merger.

What Are the Key Risks Facing Acme United?

Despite the strong Q2 performance, several structural and external risks pose challenges to sustained profitability. The company faces potential headwinds from ongoing tariff impacts, which have already necessitated the strategic inventory transition mentioned earlier . Freight costs and currency fluctuations add another layer of uncertainty, particularly given the company's international operations. The Canadian market, in particular, has shown uneven performance, lagging behind other regions and contributing to geographic disparities in revenue growth .

Furthermore, the company's seasonal business model introduces volatility into quarterly earnings. Historical data indicates that the fiscal quarter ending in June consistently delivers peak performance, driven by high gross margins and operating leverage. Conversely, other quarters may face margin compression due to lower seasonal demand and higher relative operating expenses . For the fiscal year ending March 2026, while total revenues are projected to grow, operating income is forecast to decline due to a 25% surge in other operating expenses, highlighting the importance of seasonal timing in evaluating the company's financial health . Investors must account for this volatility when assessing long-term valuation and growth prospects.

The combination of strategic acquisitions, margin expansion, and seasonal dynamics creates a complex investment thesis for Acme United. While the Q2 2026 results demonstrate strong execution and growth potential, the ongoing challenges related to SG&A expenses, tariffs, and geographic performance require careful monitoring. The company's ability to navigate these headwinds while successfully integrating MyMedic will be critical in determining its future trajectory in the competitive market landscape.